NCT05161741View on ClinicalTrials.gov

Research on Human Insulin rDNA Safety and Efficacy in Patients With Type 2 Diabetes Mellitus

PHASE4CompletedINTERVENTIONAL

Enrollment

238

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

November 30, 2022

Study Completion Date

November 30, 2022

Conditions

Adverse Drug EventEffect of DrugType 2 Diabetes Treated With Insulin

Interventions

DRUG

Insulin

Human rDNA Insulin (Insuget, local brand of Getz Pharma)

Trial Locations (1)

54500

Social Security Hospital, Lahore

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Getz Pharma

INDUSTRY